Becton, Dickinson and Company $BDX Stock: GRIMES & Co WEALTH MANAGEMENT LLC Increases Holdings

Key Points

• GRIMES & Co Wealth Management increased its Becton Dickinson stake by 352.7% in the third quarter, ending the period with 6,632 shares valued at about $1.19 million.
• BD reported quarterly EPS of $3.23, topping the $3.14 consensus, while revenue of $4.98 billion also beat expectations and grew 5.4% year over year. The company guided to fiscal 2026 EPS of $12.62–$12.72.
• Analysts’ consensus rating is “Moderate Buy,” with an average price target of $185.07; the stock opened at $197.88 in the article’s cited session.

GRIMES & Co WEALTH MANAGEMENT LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 352.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,632 shares of the medical instruments supplier's stock after purchasing an additional 5,167 shares during the quarter. GRIMES & Co WEALTH MANAGEMENT LLC's holdings in Becton, Dickinson and Company were worth $1,187,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $3,721,533,000. State Street Corp lifted its position in Becton, Dickinson and Company by 8.5% during the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier's stock worth $2,269,960,000 after acquiring an additional 1,177,256 shares in the last quarter. First Eagle Investment Management LLC boosted its holdings in Becton, Dickinson and Company by 15.8% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier's stock worth $2,090,675,000 after acquiring an additional 1,887,224 shares during the period. Bank of America Corp DE purchased a new position in Becton, Dickinson and Company in the 2nd quarter worth approximately $474,993,000. Finally, Legal & General Group Plc grew its position in Becton, Dickinson and Company by 1.5% in the second quarter. Legal & General Group Plc now owns 2,101,695 shares of the medical instruments supplier's stock valued at $318,050,000 after acquiring an additional 30,766 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Down 0.4%

Becton, Dickinson and Company stock opened at $197.88 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $200.47. The company has a 50-day simple moving average of $186.86 and a 200-day simple moving average of $170.20. The firm has a market capitalization of $54.52 billion, a P/E ratio of 15.28, a P/E/G ratio of 13.39 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company's stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael Feld sold 165 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares of the company's stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 6,907 shares of company stock worth $1,269,128. 0.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a research note on Friday, August 7th. Wolfe Research started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, October 20th. They issued an "outperform" rating for the company. Weiss Ratings raised shares of Becton, Dickinson and Company from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, September 28th. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Friday, August 7th. Finally, Barclays started coverage on shares of Becton, Dickinson and Company in a report on Wednesday, October 7th. They issued an "underweight" rating and a $165.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.